Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6296149 | 0.98 | CYP3A4 (0.66) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL3525050 | 0.89 | ALDH1A1 (0.59) | CYP3A4ALDH1A1CYP1A2CYP2C19MAPK8 | |
| SCHEMBL30232460 | 0.88 | CYP3A4 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL30232548 | 0.86 | CYP3A4 (0.51) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL658682 | 0.86 | ALDH1A1 (0.52) | CYP3A4ALDH1A1CYP1A2CYP2C19MAPK8 | |
| SCHEMBL7148530 | 0.85 | CYP3A4 (0.72) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL3944098 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL29642680 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL138875 | 0.84 | CYP3A4 (0.75) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 | |
| SCHEMBL300007 | 0.83 | TAAR1 (0.62) | CYP3A4ALDH1A1CYP1A2CYP2C19TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | DHANOA DALJIT SINGH (US) | 2025-11-04 | — | — | US | claimed |
| US-11634428-B2 | Deuterated angiotensin-converting enzyme-2 (ACE-2) inhibitors | DHANOA DALJIT SINGH (US) | 2023-04-25 | — | — | US | claimed |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | DHANOA DALJIT SINGH (US) | 2023-02-09 | — | — | US | claimed |
| US-20220306646-A1 | Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors | DHANOA DALJIT SINGH (US) | 2022-09-29 | — | — | US | claimed |
| US-20150225378-A1 | HOMOPIPERONY LAMINE COMPOUND AND USE THEREOF | SINOCHEM CORPORATION (CN) | 2015-08-13 | — | — | US | claimed |
| EP-1904439-B1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTHECHNOLOGY CORP (US) | 2014-11-26 | — | — | EP | claimed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | claimed |
| EP-2205573-B1 | TETRAZOLE-SUBSTITUTED ARYL AMIDE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | claimed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| WO-2006138660-A2 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-28 | — | — | WO | claimed |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2006-12-21 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634428-B2 | Deuterated angiotensin-converting enzyme-2 (ACE-2) inhibitors | ACE2, ACE, REN | CYP3A4 127/4885ALDH1A1 856/4885CYP1A2 88/4885 |
| US-20230039319-A1 | DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES | AGTR2, AGTR1, EDNRA | CYP3A4 2346/4885ALDH1A1 2247/4885CYP1A2 1388/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | CYP3A4 1268/4885ALDH1A1 2432/4885CYP1A2 749/4885 |
| US-20060287317-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR1 | CYP3A4 4465/4885ALDH1A1 2654/4885CYP1A2 3594/4885 |
| US-12458624-B2 | Deuterium-enriched substituted phenoxyphenyl acetic acids and acylsulfonamides | AGTR2, AGTR1, EDNRA | CYP3A4 2346/4885ALDH1A1 2247/4885CYP1A2 1388/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | CYP3A4 554/4885ALDH1A1 123/4885CYP1A2 492/4885 |
| US-20150225378-A1 | HOMOPIPERONY LAMINE COMPOUND AND USE THEREOF | CLPP, LRRK2, MYB | CYP3A4 1974/4885ALDH1A1 3907/4885CYP1A2 1085/4885 |
| US-20220306646-A1 | Deuterated Angiotensin-Converting Enzyme-2 (ACE-2) Inhibitors | ACE2, ACE, REN | CYP3A4 127/4885ALDH1A1 856/4885CYP1A2 88/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CYP3A4 632/4885ALDH1A1 170/4885CYP1A2 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.